In this study, we are comparing different doses of CT-868 to placebo to learn more about its effectiveness in decreasing Hemoglobin A1C and in decreasing weight in people with Type 1 diabetes who are overweight or obese.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide)
Klara Klein
Medicine-Endocrinology
Clinical or Medical
Interventional
Diabetes
23-1480
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
